Coronavirus disease (Covid-19) is a respiratory tract infection caused by a newly emergent coronavirus, which was first recognized in Wuhan, China in Dec 2019. Through various mechanism action of drug which are used for the treatment of Covid-19, it is know that how actually the drug can shows its working, mechanism on this disease. Comorbidities are associated with the high mortality in patient with coronavirus disease, so they will develop a more symptoms. Peoples are suffering comorbities like Covid-19 with Diabetes, Covid-19 with Hypertension, Covid-19 and Asthma, Covid-19 and COPD, Covid-19 and HIV, etc. According to different patient age group treatment of the particular medication, dose, and route of administration should be recommend by the healthcare professional and after receiving the treatment, the patients are suffering from adverse drug reactions of some medications like allergic reactions, vomiting, dizziness, fatigue, tiredness, fever, etc and drug-drug interaction may happen. Thus, this review is all about to highlight the patients who suffering from comorbidities and to study the adverse drug reactions of the medications prescribed for patient suffering from Covid-19.
Cite this article:
Pournima Yadav, Sachin Rohane, Atish Velhal. Adverse Drug Reactions and Comorbidities in Patient Treated for COVID-19. Asian Journal of Research in Chemistry. 2021; 14(6):451-4. doi: 10.52711/0974-4150.2021.00079
Pournima Yadav, Sachin Rohane, Atish Velhal. Adverse Drug Reactions and Comorbidities in Patient Treated for COVID-19. Asian Journal of Research in Chemistry. 2021; 14(6):451-4. doi: 10.52711/0974-4150.2021.00079 Available on: https://ajrconline.org/AbstractView.aspx?PID=2021-14-6-12
1. Gl J Med. 2020 May 22; NEJMo a 20 203-212 https://www.narayanahealth.org/blog/how-comorbidiities-impacts-coronavirus/
2. Wang, H. et al. SARS coronavirus entry into host cell through a novel clathrin and caveolae- independent endocytic pathway. Cell Res. 18, 290-301 (2008).
3. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585.
4. Web MD Medical Reference Reviewed by Branilda Nazaria, MD on January 26, 2021.
5. Fernandez C., Rysa J., Almgren P., Nilsson J., Engstrom G., Orho-Melander M. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018;284(4):377–387. doi: 10.1111/joim.12783
6. Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130–137. doi: 10.1111/resp.13196.
7. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi: 10.1016/s2213-2600(20)30116-8.
8. Uhlen M., Fagerberg L., Hallstrom B.M., Lindskog C., Oksvold P., Mardinoglu A. Tissue-based map of the human proteome. Science. 2015;347(6220) 514-523 doi: 10.1126/s
9. Contoli M., Message S.D., Laza S.V., Edwards M.R., Wark P.A., Bartlett N.W. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–1026. doi: 10.1038/nm1462.
10. Pene F., Merlat A., Vabret A., Rozenberg F., Buzyn A., Dreyfus F. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis. 2003;37(7):929–932. doi: 10.1086/377612.
11. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382 (19):1787–1799. doi:10.1056/NEJMoa2001282 57.
12. Campbell R, Tycon L, Pruskowski J. Corticosteroid-Induced Psychiatric Symptoms# 323. J Palliat Med. 2017;20(3):298–299. doi:10.1089/jpm.2016.0475
13. Ou G, Bressler B, Galorport C, et al. Rate of corticosteroid-induced mood changes in patients with inflammatory bowel disease: A prospective study. J Can Assoc Gastroenterol. 2018;1(3):99–106. doi:10.1093/jcag/gwy023
14. Jun C, Liu D, Li L, et al. A preliminary study of hydroxychloroquine sulfate in patients with common 2019 coronavirus disease (COVID-19). Journal of Zhejiang University 2019; 49:215-226
15. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19-Final Report. 416-427 N En
16. Koryürek ÖM, Kalkan G. Tocilizumab: a new alternative therapy in dermatology. 912-933 Immunomodulatory Immunosuppressive Drugs Dermatol.
17. Rohane S.H., Makwana A. G., 2017. A Review on Hydrazone, the fascinating field of investigational in medicinal chemistry. Asian J Res. Chem. 10,417-30.
18. Rohane S. H., Makwana A. G., 2019. In silico study for the prediction of multiple pharmacological activities of novel hydrazone derivatives. Ind J. Chem. Sec-B. 58, 387-402.
19. Rohane S. H., Makwana A. G., 2020. Synthesis and in vitro antimycobacterial potential of novel hydrazones of eugenol. Arab J. Chem. 13, 4495-4504.
20. Rohane S. H., Aware D. V., 2021. A Role of Herbal Drug as an Immunity Booster during Covid-19 Pandemic. AJPRes. 11(3), 206-211.